Proven Results with ILARIS

ILARIS® is the first once-monthly injection that is FDA approved for active Systemic Juvenile Idiopathic Arthritis (SJIA) in children 2 years of age and older. This FDA approval was based on research that included 190 children.

100% of children with SJIA had no fever 3 days after taking their first dose of ILARIS

In a study, SJIA symptom improvements were seen after just one dose of ILARIS

3 days after taking their first dose of ILARIS, 100% of children with SJIA had no fever

Approximately 8 out of 10 children experienced improvements in their SJIA symptoms 15 days after their first dose of ILARIS

15 days after their first dose of ILARIS, approximately 8 out of 10 children experienced improvement in their SJIA symptoms (fever and painful and/or swollen joints)

ILARIS Can Reduce or Stop
Corticosteroid Use*

  • Almost half (46%) of the children whose SJIA symptoms were controlled appropriately were able to stop taking corticosteroids completely after 5 months

  • Of the children whose SJIA symptoms were controlled, nearly two-thirds (62%) of those taking ILARIS were on a lower dose of corticosteroids after 5 months

*128 patients entered the clinical study taking corticosteroids. 92 of these patients entered a part of the clinical trial to see if they could reduce or stop taking corticosteroids.

ILARIS can reduce or stop corticosteroid use
ILARIS can reduce or stop corticosteroid use

Talk to a doctor about whether ILARIS may be right for your child.

Next: Safety Considerations